Adalimumab Discount Contract
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
15 / 100
Risk factors
No estimated value or guaranteed volume; revenue depends on actual prescriptions and discounts.
Structured data indicates EU-funded, but XML notice states no EU funds. This may affect audit requirements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Conclusion of discount contracts for Adalimumab
- 24-month term from 01.08.2025 to 31.07.2027
Show full summary
Open-house procedure by Techniker Krankenkasse and participating health insurances for discount contracts on Adalimumab (pharmaceutical product) under §130a Abs. 8 SGB V. Contracts are concluded with any eligible pharmaceutical entrepreneur on standard terms, without exclusivity. Term: 01.08.2025 – 31.07.2027 (24 months). No estimated value provided. No competitive award; eligibility criteria must be met.
Risks
No estimated value or guaranteed volume; revenue depends on actual prescriptions and discounts.
Structured data indicates EU-funded, but XML notice states no EU funds. This may affect audit requirements.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4(18) AMG
- Must hold a valid marketing authorization for Adalimumab or be entitled to market it
- Must have seat in Germany, EU, or EEA
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Adalimumab Discount Contract
Conclusion of discount contracts for the active ingredient Adalimumab under an open-house procedure. No exclusivity, standard conditions.
Location
Duration
Category
Award Criteria
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Adalimumab im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Adalimumab im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 12 Jun 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 382585-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
15 / 100
Risk factors
No estimated value or guaranteed volume; revenue depends on actual prescriptions and discounts.
Structured data indicates EU-funded, but XML notice states no EU funds. This may affect audit requirements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications